17:19 , Aug 3, 2018 |  BC Week In Review  |  Financial News

CRISPR diagnostics play Mammoth raises $23M series A

Mammoth Biosciences (San Francisco, Calif.) raised $23 million on July 31 in a series A round led by Mayfield Partners, with participation from fellow seed investors NFX and 8VC. Co-founder and CEO Trevor Martin told BioCentury...
16:03 , Jul 31, 2018 |  BC Extra  |  Financial News

CRISPR diagnostics play Mammoth raises $23M series A

Mammoth Biosciences (San Francisco, Calif.) raised $23 million in a series A round led by Mayfield Partners, with participation from fellow seed investors NFX and 8VC. Co-founder and CEO Trevor Martin told BioCentury the funds will...
19:51 , Apr 27, 2018 |  BC Week In Review  |  Company News

Mammoth emerges to bring CRISPR into diagnostic space

Mammoth Biosciences (San Francisco, Calif.) debuted on April 26 with a CRISPR-based diagnostic platform and an exclusive license to IP covering work from CRISPR pioneer Jennifer Doudna. While CRISPR-based therapeutics have garnered the most attention...
16:11 , Apr 26, 2018 |  BC Extra  |  Company News

Mammoth emerges, among first diagnostic-focused CRISPR companies

Mammoth Biosciences (San Francisco, Calif.) debuted on Thursday with a CRISPR-based diagnostic platform and an exclusive license to IP covering work from CRISPR pioneer Jennifer Doudna. While CRISPR-based therapeutics have garnered the most attention from...
16:09 , Apr 26, 2018 |  BC Innovations  |  Emerging Company Profile

Mammoth makes Dx CRISPR

Mammoth Biosciences emerged from stealth with an exclusive license to Jennifer Doudna’s CRISPR-based diagnostics technology, which could enable faster diagnosis of a range of diseases than PCR-based sequencing and culture-based techniques and be more adaptable...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Synthetic biology play Senti emerges with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co.,...
12:35 , Feb 27, 2018 |  BC Extra  |  Financial News

Synthetic biology play Senti debuts with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co.,...
12:33 , Feb 27, 2018 |  BC Innovations  |  Emerging Company Profile

Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes...
15:04 , Dec 22, 2017 |  BC Week In Review  |  Company News

BiomX acquires microbiome company RondinX

BiomX Ltd. (Ness Ziona, Israel) acquired fellow microbiome company RondinX (Tel Aviv, Israel), including its computational discovery platform. BiomX said it also gains a pipeline of undisclosed microbial targets that are being validated to treat...
21:11 , Dec 19, 2017 |  BC Extra  |  Company News

BiomX acquires microbiome company RondinX

BiomX Ltd. (Ness Ziona, Israel) said it acquired fellow microbiome company RondinX (Tel Aviv, Israel), including its computational discovery platform. BiomX said it also gains a pipeline of undisclosed microbial targets that are being validated...